Transversus Abdominis Plane Block During Kidney Transplant Surgery

Transversus Abdominis Plane Block During Kidney Transplant Surgery: Prospective Controlled Randomized Double-blind Trial Comparing Ropivacaine 0.2% With Placebo.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02080728

Enrollment

Registered

2014-03-06

Start date

2013-07-23

Completion date

2014-07-09

Last updated

2018-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant

Brief summary

The surgeon places the catheter in the thickness of the oblique internal and transverse muscles at the moment the wall is closed, under visual control. A multiperforated catheter whose length corresponds to that of the incision is chosed. The catheter will deliver one of two products chosen at random: either ropivacaine or placebo. This study will evaluate postoperative pain during the first 24 hours thanks to a recognized indicator the VAS (Visual Analogue pain Scale). The total consumption of analgesics will also be recorded, starting with the titration of morphine in the post-op room, and then the consumption of classical analgesics in the nephrology department. These will only be given if the VAS score is equal to 4 or above. This is a prospective, single-centre, controlled, double blind study of ropivacaïne 0.2% versus placebo in continuous TAP block during the first 24 hours after the operation in patients undergoing kidney transplant surgery.

Interventions

DRUGRopivacaine 500mg/100ml Naropeine

DRUG0.9% sodium chloride BAXTER

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patient opéré for kidney transplant * Patients who have provided written informed consent * Patients with national health insurance cover * Patients aged 18 years and above

Exclusion criteria

* Pregnant or breast-feeding women * allergies/hypersensitivity to paracetamol (or propacetamol chlorhydrate (paracetamol pro-drug) or one of its excipients), to local anesthetics, morphines (or other constituents) * patients under guardianship or ward of court

Design outcomes

Primary

Measure	Time frame
Mesurement of VAS (Visual analogue scale) scores for pain	During the first 24 hours post-op

Secondary

Measure	Time frame
Measurement of analgesic consomption	During the first 24 hours post-op

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026